Lepu Biopharma (2157) Announces Continuing Connected Transaction with Lepu Medical

Bulletin Express11-28

Lepu Biopharma Co., Ltd. (stock code: 2157) has entered into a CDMO Services Framework Agreement with Lepu Medical on November 28, 2025. Under this agreement, Lepu Biopharma will provide contract development and manufacturing (CDMO) services for Lepu Medical’s GLP-1 and related product development needs.

The arrangement will run from January 1, 2026, to December 31, 2026, with a proposed cap of RMB18.2 million. The company cited its GMP-compliant bioreactor production line and established production management team as key drivers for this collaboration, expecting to more effectively utilize excess manufacturing capacity while supporting Lepu Medical’s clinical and production requirements.

Because Lepu Medical holds approximately 12.49% of Lepu Biopharma’s issued share capital, the transaction constitutes a continuing connected transaction under Chapter 14A of the Listing Rules. Relevant percentage ratios remain below 5%, so the agreement is subject only to reporting, announcement, and annual review requirements, without necessitating shareholders’ approval.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1179033970?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-28 16:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179033970","market":"hk","top_or_hot":-1,"title":"Lepu Biopharma (2157) Announces Continuing Connected Transaction with Lepu Medical","media":"Bulletin Express","content":"<p>Lepu Biopharma Co., Ltd. (stock code: 2157) has entered into a CDMO Services Framework Agreement with Lepu Medical on November 28, 2025. Under this agreement, Lepu Biopharma will provide contract development and manufacturing (CDMO) services for Lepu Medical’s GLP-1 and related product development needs.</p>\n<p>The arrangement will run from January 1, 2026, to December 31, 2026, with a proposed cap of RMB18.2 million. The company cited its GMP-compliant bioreactor production line and established production management team as key drivers for this collaboration, expecting to more effectively utilize excess manufacturing capacity while supporting Lepu Medical’s clinical and production requirements.</p>\n<p>Because Lepu Medical holds approximately 12.49% of Lepu Biopharma’s issued share capital, the transaction constitutes a continuing connected transaction under Chapter 14A of the Listing Rules. Relevant percentage ratios remain below 5%, so the agreement is subject only to reporting, announcement, and annual review requirements, without necessitating shareholders’ approval.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lepu Biopharma (2157) Announces Continuing Connected Transaction with Lepu Medical</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLepu Biopharma (2157) Announces Continuing Connected Transaction with Lepu Medical\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2025-11-28 16:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Lepu Biopharma Co., Ltd. (stock code: 2157) has entered into a CDMO Services Framework Agreement with Lepu Medical on November 28, 2025. Under this agreement, Lepu Biopharma will provide contract development and manufacturing (CDMO) services for Lepu Medical’s GLP-1 and related product development needs.</p>\n<p>The arrangement will run from January 1, 2026, to December 31, 2026, with a proposed cap of RMB18.2 million. The company cited its GMP-compliant bioreactor production line and established production management team as key drivers for this collaboration, expecting to more effectively utilize excess manufacturing capacity while supporting Lepu Medical’s clinical and production requirements.</p>\n<p>Because Lepu Medical holds approximately 12.49% of Lepu Biopharma’s issued share capital, the transaction constitutes a continuing connected transaction under Chapter 14A of the Listing Rules. Relevant percentage ratios remain below 5%, so the agreement is subject only to reporting, announcement, and annual review requirements, without necessitating shareholders’ approval.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02157","symbol_name":"乐普生物-B","start_time":0,"source_url":"","article_id":"1179033970","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179033970","pubTimestamp":1764319421,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Lepu Biopharma Co., Ltd. (stock code: 2157) has entered into a CDMO Services Framework Agreement with Lepu Medical on November 28, 2025. Under this agreement, Lepu Biopharma will provide contract...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02157":"乐普生物-B"},"translate_title":"乐普生物(2157)公布与乐普医疗的持续关连交易","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02157":1},"content_text":"Lepu Biopharma Co., Ltd. (stock code: 2157) has entered into a CDMO Services Framework Agreement with Lepu Medical on November 28, 2025. Under this agreement, Lepu Biopharma will provide contract development and manufacturing (CDMO) services for Lepu Medical’s GLP-1 and related product development needs.\nThe arrangement will run from January 1, 2026, to December 31, 2026, with a proposed cap of RMB18.2 million. The company cited its GMP-compliant bioreactor production line and established production management team as key drivers for this collaboration, expecting to more effectively utilize excess manufacturing capacity while supporting Lepu Medical’s clinical and production requirements.\nBecause Lepu Medical holds approximately 12.49% of Lepu Biopharma’s issued share capital, the transaction constitutes a continuing connected transaction under Chapter 14A of the Listing Rules. Relevant percentage ratios remain below 5%, so the agreement is subject only to reporting, announcement, and annual review requirements, without necessitating shareholders’ approval.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"corporation,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1179033970","isCrawlerRequest":true}